Medison Pharma and Immunocore Announce ANVISA Approval of KIMMTRAK® for the Treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in Brazil[¹]

Medison Pharma

KIMMTRAK (tebentafuspe) é o primeiro e único tratamento aprovado para pacientes adultos brasileiros que vivem com esta doença [1]View original content:https://www.prnewswire.com/br/comunicados-para-a-imprensa/medison-pharma-and-immunocore-announce-anvisa-approval-of-kimmtrak-tebentafuspe-for-the-treatment-of-hla-a0201-positive-adults-with-unresectable-or-metastatic-uveal-melanoma-in-brazil-302404306.html

FONTE Medison Pharma